Modest Survival Gains in Metastatic Prostate Cancer Reported - Cancer Therapy Advisor

-

Several new drugs have been approved for metastatic prostate cancer (PCa) since 2004, but declines in PCa screening due to a 2012 US Preventive Screening Task Force (USPSTF) recommendation against it may have eroded drug-related survival gains, according to investigators of a new study presented during the American Urological Association 2020 Virtual Experience.

Michael Adam Feuerstein, MD, of Northwell Health in New York City, and colleagues analyzed data from 34,888 men (median age 72 years) with metastatic PCa from 18 Surveillance, Epidemiology, and End Results (SEER) registries to better understand disease trends. From 2004 to 2015, there was an uptick in de novo M1 diagnoses from 10.2 to 12.1 per 100,000. The incidence of PCa with bone metastasis with or without lymph node involvement (M1b) increased, whereas incidence of disease in non-regional lymph nodes (M1a) and distant metastatic disease (M1c) remained stable.

Overall survival at 2 years for M1 disease increased only slightly from 50% in 2004 to 54% in 2014; during that same period, cancer-specific survival at 2 years rose from 60% to 63%.

Related Articles

“The survival trend may be less pronounced than expected due to decreased screening and later diffusion of effective treatments,” according to Dr Feuerstein’s team.

Reference

Rasul R, Golden A, Feuerstein M, et al. Trends in incidence and survival among men with metastatic prostate cancer: SEER analysis 2004-2015. Presented at the American Urological Association 2020 Virtual Experience, May 15-19, 2020. Abstract MP64-05.

This article originally appeared on Renal and Urology News

Topics:

Prostate Cancer


Comments

Post a Comment

Popular posts from this blog

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

-
Image
efudex side effects :: Article Creator Inmates Given Ivermectin In Jail Will Each Get $2,000 After Settlement Your browser is not supporteddetroitnews.Com detroitnews.Com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use. Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on detroitnews.Com Efudex Cream Efudex Cream Generic Name & Formulations General Description Fluorouracil 5%. Pharmacological Class Antimetabolite. How Supplied Soln (w. Drop dispenser)—10mL, 25mL; Crm—40g Efudex Cream Indications Indications Multiple actinic or solar keratoses. Superficial basal cell carcinoma when conventional therapy is impractical (5% only); see full labeling. Efudex Cream Dosage and Administration Adult Keratoses: Apply twice daily until eros
Read more

Early symptoms of cancer in males: Common warning signs

-
Image
fluciclovine f 18 :: Article Creator The U.S. Navy Might Be Done With The F/A-18 Super Hornet Fighter Will The U.S. Navy Receive Its Final F/A-18 Super Hornets? - Around the holidays, money can be tight, a fact that the United States Navy has also learned as its negotiations to buy the last batch of Super Hornets are reportedly stalled over the growing price tag. USNI News reported on Tuesday that the contract for the U.S. Navy to purchase the final twenty F/A-18 E/F Super Hornets from aerospace giant Boeing appears to be at a standstill. The Navy continues to work with Boeing on the contract for the 20 congressionally added Super Hornet aircraft. Ongoing contract negotiations cannot be discussed at this time," Capt. Michael Burks, the program manager for the F/A-18 and EA-18G office at Naval Air Systems Command, told USNI News in a statement. Previous estimates put the unit cost of the final batch of aircraft at $55.7 million, and la
Read more

20 Famous Men Who Have Had Prostate Cancer

-
Image
leukemia treatment options :: Article Creator Current And Breakthrough Treatments For Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the immune system. Because it's slow-growing, many people with CLL won't need to start treatment for many years after their diagnosis. Once the cancer begins to grow, there are many available treatment options that can help people achieve remission. This means people can experience long periods of time when there's no sign of cancer in their bodies. The exact treatment option that you'll receive depends on a variety of factors. This includes: whether your CLL is symptomatic the stage of the CLL, based on results of blood tests and a physical exam your age your overall health While there's no cure for CLL yet, breakthroughs in the field are on the horizon. Doctors typically stage CLL using a system called the Rai system. Low
Read more